Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pregabalin + toludesvenlafaxine
- Development stage
- Unknown
- Lead developer
- Beijing Tiantan Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pregabalin + toludesvenlafaxine is a combination therapy being investigated by Beijing Tiantan Hospital for the treatment of fibromyalgia. This combination pairs pregabalin, a gabapentinoid that acts as a ligand for the alpha-2/delta subunit of voltage-gated calcium channels to reduce excitatory neurotransmitter release, with toludesvenlafaxine (LY03005), a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). While toludesvenlafaxine is primarily characterized as a selective serotonin and norepinephrine reuptake inhibitor (SNRI) in some clinical contexts, it also inhibits dopamine reuptake. The rationale for the combination is to provide synergistic pain relief by targeting both central sensitization (via pregabalin) and descending inhibitory pain pathways (via toludesvenlafaxine) associated with fibromyalgia.
- Other names
- pregabalin + desvenlafaxinepregabalin + LY03005pregabalin + Ruoxinlin
02
Targets
DAT (Dopamine plasma membrane transport protein)CACNA2D2 (α2δ-2)SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)
Beyond the preview
Go deeper on pregabalin + toludesvenlafaxine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pregabalin + toludesvenlafaxine.